196 related articles for article (PubMed ID: 28555624)
1. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.
Sobot D; Mura S; Yesylevskyy SO; Dalbin L; Cayre F; Bort G; Mougin J; Desmaële D; Lepetre-Mouelhi S; Pieters G; Andreiuk B; Klymchenko AS; Paul JL; Ramseyer C; Couvreur P
Nat Commun; 2017 May; 8():15678. PubMed ID: 28555624
[TBL] [Abstract][Full Text] [Related]
2. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Sobot D; Mura S; Rouquette M; Vukosavljevic B; Cayre F; Buchy E; Pieters G; Garcia-Argote S; Windbergs M; Desmaële D; Couvreur P
Mol Ther; 2017 Jul; 25(7):1596-1605. PubMed ID: 28606375
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine lipid prodrug nanoparticles: Switching the lipid moiety and changing the fate in the bloodstream.
Coppens E; Desmaële D; Naret T; Garcia-Argote S; Feuillastre S; Pieters G; Cailleau C; Paul JL; Prost B; Solgadi A; Michel JP; Noiray M; Couvreur P; Mura S
Int J Pharm; 2021 Nov; 609():121076. PubMed ID: 34481886
[TBL] [Abstract][Full Text] [Related]
4. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
[TBL] [Abstract][Full Text] [Related]
5. Low-Density Lipoproteins and Human Serum Albumin as Carriers of Squalenoylated Drugs: Insights from Molecular Simulations.
Yesylevskyy SO; Ramseyer C; Savenko M; Mura S; Couvreur P
Mol Pharm; 2018 Feb; 15(2):585-591. PubMed ID: 29298487
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of gemcitabine affinity for biomembranes by conjugation with squalene: differential scanning calorimetry and Langmuir-Blodgett studies using biomembrane models.
Castelli F; Sarpietro MG; Micieli D; Stella B; Rocco F; Cattel L
J Colloid Interface Sci; 2007 Dec; 316(1):43-52. PubMed ID: 17765257
[TBL] [Abstract][Full Text] [Related]
8. Squalenoylation: a generic platform for nanoparticular drug delivery.
Desmaële D; Gref R; Couvreur P
J Control Release; 2012 Jul; 161(2):609-18. PubMed ID: 21840355
[TBL] [Abstract][Full Text] [Related]
9. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
[TBL] [Abstract][Full Text] [Related]
10. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
11. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane.
Ambike A; Rosilio V; Stella B; Lepêtre-Mouelhi S; Couvreur P
Langmuir; 2011 Apr; 27(8):4891-9. PubMed ID: 21413743
[TBL] [Abstract][Full Text] [Related]
12. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
13. In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene-Based Prodrug Nanoparticles.
Cayre F; Mura S; Andreiuk B; Sobot D; Gouazou S; Desmaële D; Klymchenko AS; Couvreur P
Adv Healthc Mater; 2018 Feb; 7(3):. PubMed ID: 29195020
[TBL] [Abstract][Full Text] [Related]
14. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
15. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ
ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019
[TBL] [Abstract][Full Text] [Related]
16. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
[TBL] [Abstract][Full Text] [Related]
17. Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity.
Lepeltier E; Bourgaux C; Maksimenko A; Meneau F; Rosilio V; Sliwinski E; Zouhiri F; Desmaële D; Couvreur P
Langmuir; 2014 Jun; 30(22):6348-57. PubMed ID: 24835925
[TBL] [Abstract][Full Text] [Related]
18. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
20. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.
Gaudin A; Song E; King AR; Saucier-Sawyer JK; Bindra R; Desmaële D; Couvreur P; Saltzman WM
Biomaterials; 2016 Oct; 105():136-144. PubMed ID: 27521616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
